--- title: "Cartesian Therapeutics (RNAC) stock and investor profile" url: "https://aibio.space/companies/cartesian-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Cartesian Therapeutics, Inc. (NASDAQ: RNAC), United States. The directory classifies it as Biotechnology." --- RNAC Cartesian Therapeutics, Inc. NASDAQ · United States # Cartesian Therapeutics (RNAC) news Debt Financing · 2026-05-26 ## [Cartesian Therapeutics signs term loan of up to $150.0 million with K2 HealthVentures](https://aibio.space/news/cartesian-therapeutics-signs-term-loan-up-150-0-million-k2/) Cartesian drew $50.0 million at closing under a senior secured loan that can reach $150.0 million, with the lenders able to convert up to $15.0 million into common stock at $8.2526 a share. The loan carries a minimum cash covenant starting April 1, 2027, and the 8-K does not name the individual lenders. ## Latest Cartesian Therapeutics news 1. 2026-05-22 Debt Financing [Cartesian Therapeutics signs up to $150.0 million senior secured term loans](https://aibio.space/news/cartesian-therapeutics-signs-up-150-0-million-senior-secured-term/) The loans carry a variable rate of at least 8.95% and mature on June 1, 2030. Only the first $50.0 million was funded at closing, and the two later tranches depend on milestones. ## Cartesian Therapeutics at a glance - **Ticker**: RNAC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $147.6 million ### Related companies - [Abpro Holdings](https://aibio.space/companies/abpro/) OTC: ABPO - [Entrada Therapeutics](https://aibio.space/companies/entrada-therapeutics/) NASDAQ: TRDA - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN - [Enzolytics](https://aibio.space/companies/enzolytics/) OTC: ENZC - [Replimune Group](https://aibio.space/companies/replimune/) NASDAQ: REPL - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) NASDAQ: TRVI - [Elutia](https://aibio.space/companies/elutia/) NASDAQ: ELUT - [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) NASDAQ: REVB ### Also on NASDAQ - [Kymera Therapeutics](https://aibio.space/companies/kymera-therapeutics/) KYMR - [Enlivex](https://aibio.space/companies/enlivex/) ENLV - [Fennec Pharmaceuticals](https://aibio.space/companies/fennec-pharmaceuticals/) FENC - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) ENVB - [electroCore](https://aibio.space/companies/electrocore/) ECOR - [Pulsenmore](https://aibio.space/companies/pulsenmore/) PLSM ## What Cartesian Therapeutics does Cartesian Therapeutics is a late clinical-stage biotechnology company developing cell therapy for autoimmune diseases. It uses a proprietary technology and manufacturing platform that introduces mRNA into cells, which the company says degrades naturally and does not integrate into the cell's genetic material. Its lead cell therapy product candidate, Descartes-08, is an autologous CAR-T product targeting B-cell maturation antigen (BCMA). The company is developing Descartes-08 for generalized myasthenia gravis (MG) and for myositis, specifically moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome. The Phase 3 AURORA trial is pursuing the acetylcholine receptor autoantibody positive (AChR+) subtype of MG. Descartes-08 has Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA for MG, and Rare Pediatric Disease Designation for juvenile dermatomyositis. The company says its CAR-T administration has been observed to provide deep and durable benefits through 12 months and is designed not to require preconditioning chemotherapy. The company was formerly known as Selecta Biosciences, and it is headquartered in Frederick, Maryland. | Product or program | What it is | Stage | |---|---|---| | Descartes-08 in generalized myasthenia gravis | Autologous BCMA-targeting mRNA CAR-T product for AChR+ generalized myasthenia gravis | Phase 3 AURORA trial | | Descartes-08 in myositis | Autologous BCMA-targeting CAR-T for moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome | Clinical development | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm). ## Cartesian Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | [$38.9 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | | Research and development | [$58.0 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | [$45.1 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | | Net income (loss) | [-$130.3 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | [-$77.4 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | | Cash from operations | [-$73.9 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | [-$23.7 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | | Cash and equivalents | [$125.1 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000101/) | [$212.6 million](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $147.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cartesian Therapeutics What is the ticker symbol of Cartesian Therapeutics? Cartesian Therapeutics, Inc. trades under the ticker RNAC on NASDAQ. Where is Cartesian Therapeutics listed? Cartesian Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1S70. What is the SEC CIK of Cartesian Therapeutics? The SEC Central Index Key (CIK) for Cartesian Therapeutics, Inc. is 1453687. Its filings are on SEC EDGAR. How many shares does Cartesian Therapeutics have outstanding? 30,255,352 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Cartesian Therapeutics listed under? Our directory records Cartesian Therapeutics, Inc. under United States. What does Cartesian Therapeutics do? Our directory classifies Cartesian Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Cartesian Therapeutics? The ISIN recorded for Cartesian Therapeutics, Inc. is US8162123025. Does aibio.space cover Cartesian Therapeutics? aibio.space lists Cartesian Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cartesian Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Cartesian Therapeutics develop? Cartesian Therapeutics is a late clinical-stage biotechnology company developing cell therapy for autoimmune diseases. It uses a proprietary technology and manufacturing platform that introduces mRNA into cells, which the company says degrades naturally and does not integrate into the cell's genetic material. What is Descartes-08 in generalized myasthenia gravis from Cartesian Therapeutics? Descartes-08 in generalized myasthenia gravis: Autologous BCMA-targeting mRNA CAR-T product for AChR+ generalized myasthenia gravis Stage: Phase 3 AURORA trial. What is Descartes-08 in myositis from Cartesian Therapeutics? Descartes-08 in myositis: Autologous BCMA-targeting CAR-T for moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome Stage: Clinical development. What was Cartesian Therapeutics's revenue last year? $2.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Cartesian Therapeutics profitable? Cartesian Therapeutics, Inc. reported a net loss of $130.3 million for the fiscal year ended Dec 31, 2025, and used $73.9 million of cash in operations, per its annual report to the SEC. How much does Cartesian Therapeutics spend on research and development? $58.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Cartesian Therapeutics Members talk about Cartesian Therapeutics (RNAC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cartesian Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-26 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnac-20260522.htm) 2. 2026-03-09 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm) 3. 2025-03-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1453687/000145368725000060/rnac-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RNAC on TradingView](https://www.tradingview.com/symbols/NASDAQ-RNAC/). ## SEC filings and registration - **SEC name**: Cartesian Therapeutics, Inc. - **CIK**: 1453687 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RNAC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 7495 NEW HORIZON WAY, FREDERICK, MD, 21703 - **Phone**: 301-348-8698 - **Shares outstanding**: 30,255,352 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: SELECTA BIOSCIENCES INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/rnac-20260929.htm) filed 2026-09-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000101/rnac-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/rnac-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000090/rnac-20260612.htm) filed 2026-06-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/ef20075770_8k.htm) filed 2026-06-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnac-20260522.htm) filed 2026-05-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000082/rnac-20260331.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/rnac-20260430.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001453687), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cartesian Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RNAC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cartesian Therapeutics, Inc. - **Ticker**: RNAC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US8162123025 - **Other listed symbols**: GETTEX:1S70 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RNAC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cartesian-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cartesian Therapeutics (RNAC) stock and investor profile", 2026-10-31, https://aibio.space/companies/cartesian-therapeutics/